Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.65
CBPO's Cash to Debt is ranked higher than
53% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CBPO: 0.65 )
CBPO' s 10-Year Cash to Debt Range
Min: 0.65   Max: 306.77
Current: 0.65

0.65
306.77
Equity to Asset 0.45
CBPO's Equity to Asset is ranked higher than
61% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBPO: 0.45 )
CBPO' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.67
Current: 0.45

0.29
0.67
Interest Coverage 76.59
CBPO's Interest Coverage is ranked higher than
55% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 76.59 )
CBPO' s 10-Year Interest Coverage Range
Min: 6.9   Max: 93.8
Current: 76.59

6.9
93.8
F-Score: 5
Z-Score: 6.68
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 45.62
CBPO's Operating margin (%) is ranked higher than
98% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CBPO: 45.62 )
CBPO' s 10-Year Operating margin (%) Range
Min: 21.04   Max: 51.58
Current: 45.62

21.04
51.58
Net-margin (%) 29.35
CBPO's Net-margin (%) is ranked higher than
96% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. CBPO: 29.35 )
CBPO' s 10-Year Net-margin (%) Range
Min: 1.06   Max: 26.85
Current: 29.35

1.06
26.85
ROE (%) 31.89
CBPO's ROE (%) is ranked higher than
97% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CBPO: 31.89 )
CBPO' s 10-Year ROE (%) Range
Min: 2.86   Max: 42.14
Current: 31.89

2.86
42.14
ROA (%) 16.06
CBPO's ROA (%) is ranked higher than
96% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. CBPO: 16.06 )
CBPO' s 10-Year ROA (%) Range
Min: 1.08   Max: 23.86
Current: 16.06

1.08
23.86
ROC (Joel Greenblatt) (%) 60.40
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. CBPO: 60.40 )
CBPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 54.51   Max: 254.82
Current: 60.4

54.51
254.82
Revenue Growth (3Y)(%) 8.50
CBPO's Revenue Growth (3Y)(%) is ranked higher than
84% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CBPO: 8.50 )
CBPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.3   Max: 57.5
Current: 8.5

8.3
57.5
EBITDA Growth (3Y)(%) 5.50
CBPO's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CBPO: 5.50 )
CBPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 5.5   Max: 72.3
Current: 5.5

5.5
72.3
EPS Growth (3Y)(%) 15.10
CBPO's EPS Growth (3Y)(%) is ranked higher than
88% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CBPO: 15.10 )
CBPO' s 10-Year EPS Growth (3Y)(%) Range
Min: 6.7   Max: 156.1
Current: 15.1

6.7
156.1
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CBPO Guru Trades in Q4 2013

Jim Simons 118,400 sh (+25.29%)
Chuck Royce 2,900 sh (unchged)
» More
Q1 2014

CBPO Guru Trades in Q1 2014

Jim Simons 130,375 sh (+10.11%)
Chuck Royce 2,900 sh (unchged)
» More
Q2 2014

CBPO Guru Trades in Q2 2014

Jim Simons 200,100 sh (+53.48%)
Chuck Royce 2,900 sh (unchged)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

CBPO Guru Trades in Q3 2014

Jim Simons 222,600 sh (+11.24%)
Chuck Royce 2,900 sh (unchged)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.10
CBPO's P/E(ttm) is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 26.10 )
CBPO' s 10-Year P/E(ttm) Range
Min: 2.92   Max: 124.23
Current: 26.1

2.92
124.23
P/B 8.52
CBPO's P/B is ranked higher than
67% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. CBPO: 8.52 )
CBPO' s 10-Year P/B Range
Min: 0.84   Max: 8.74
Current: 8.52

0.84
8.74
P/S 7.60
CBPO's P/S is ranked higher than
85% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. CBPO: 7.60 )
CBPO' s 10-Year P/S Range
Min: 0.68   Max: 7.8
Current: 7.6

0.68
7.8
PFCF 28.94
CBPO's PFCF is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 28.94 )
CBPO' s 10-Year PFCF Range
Min: 1.92   Max: 30.83
Current: 28.94

1.92
30.83
EV-to-EBIT 16.94
CBPO's EV-to-EBIT is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 16.94 )
CBPO' s 10-Year EV-to-EBIT Range
Min: 1.2   Max: 18.1
Current: 16.94

1.2
18.1
PEG 1.53
CBPO's PEG is ranked higher than
99% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.53 )
CBPO' s 10-Year PEG Range
Min: 0.42   Max: 1.6
Current: 1.53

0.42
1.6
Shiller P/E 54.67
CBPO's Shiller P/E is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 54.67 )
CBPO' s 10-Year Shiller P/E Range
Min: 27.89   Max: 56.02
Current: 54.67

27.89
56.02
Current Ratio 2.14
CBPO's Current Ratio is ranked higher than
61% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CBPO: 2.14 )
CBPO' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.78
Current: 2.14

1.03
5.78
Quick Ratio 1.39
CBPO's Quick Ratio is ranked higher than
58% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CBPO: 1.39 )
CBPO' s 10-Year Quick Ratio Range
Min: 0.54   Max: 3.92
Current: 1.39

0.54
3.92

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.98
CBPO's Price/Tangible Book is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. CBPO: 8.98 )
CBPO' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 16.55
Current: 8.98

1.16
16.55
Price/DCF (Projected) 2.43
CBPO's Price/DCF (Projected) is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 2.43 )
CBPO' s 10-Year Price/DCF (Projected) Range
Min: 0.98   Max: 1.95
Current: 2.43

0.98
1.95
Price/Median PS Value 3.82
CBPO's Price/Median PS Value is ranked higher than
70% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CBPO: 3.82 )
CBPO' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 3.07
Current: 3.82

0.44
3.07
Price/Peter Lynch Fair Value 1.56
CBPO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 1.56 )
CBPO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.53   Max: 1.25
Current: 1.56

0.53
1.25
Price/Graham Number 2.70
CBPO's Price/Graham Number is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBPO: 2.70 )
CBPO' s 10-Year Price/Graham Number Range
Min: 0.38   Max: 3.79
Current: 2.7

0.38
3.79
Earnings Yield (Greenblatt) 5.90
CBPO's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. CBPO: 5.90 )
CBPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.5   Max: 84.3
Current: 5.9

5.5
84.3
Forward Rate of Return (Yacktman) 18.98
CBPO's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 16.92 vs. CBPO: 18.98 )
CBPO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 18.9   Max: 35.7
Current: 18.98

18.9
35.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany,
China Biologic Products, Inc. was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., which is the survivor of a merger with GRC Holdings, Inc. on May 28, 2003. On January 10, 2007, the Company was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. It is a biopharmaceutical company which is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company has two majority subsidiaries, Shandong Taibang, a company based in Tai'an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. The Company's products are human albumin and immunoglobulin products. Albumin has been used for almost 50 years to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. Immunoglobulin is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as the principal raw material. Human albumin and human immunoglobulin for intravenous injection, or IVIG products, are the top-selling products. The Company sells its products primarily to hospitals and inoculation centers in the PRC directly or through approved distributors.
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 
China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biol Dec 18 2008 

More From Other Websites
Nasdaq stocks posting largest percentage increases Dec 19 2014
Newly Profitable Medivation Riding High On Drug Sales Nov 28 2014
CHINA BIOLOGIC PRODUCTS, INC. Financials Nov 14 2014
China Biologic Products (CBPO) Crumbles: Stock Falls by 6.7% Nov 11 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 06 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 05 2014
China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2014 Nov 05 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 10-Q, Quarterly Report Nov 05 2014
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 03 2014
China Biologic to Build Two New Plasma Collection Stations in Hebei Province Nov 03 2014
China Biologic to Report Third Quarter 2014 Financial Results Oct 30 2014
China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex... Oct 17 2014
A Chinese Biopharmaceutical Company Under The Radar Oct 08 2014
Cytori Therapeutics (CYTX) Jumps: Stock Rises 6.4% Sep 22 2014
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Sep 18 2014
Regeneron Gets Breakthrough Therapy Status for Eylea Sep 17 2014
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% Sep 10 2014
ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% Sep 08 2014
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% Sep 08 2014
China Biologic to Participate in Upcoming Investor Conferences Sep 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK